Development of Linagliptin Ultra Fine Solid Supersaturated Bio-SNEDDS Using Triangular Mixture Design for Enhancement of Oral Bioavailability: Impact of P-gp Inhibition
Hend Mohammed Mansour, Abd El-Gawad H. Abd El-Gawad & Mariza Fouad Boughdady · Journal of Pharmaceutical Research International · 2023
Linagliptin (LIN) is a newly developed dipeptidyl peptidase 4 (DPP-4) inhibitor oral antidiabetic drug. LIN is considered a P-gp substrate, thus suffers from poor bioavailability (< 30%). The aim of this study was to develop and characterize LIN bioactive self-nanoemulsifying...
Open access
Research Article
10.9734/jpri/2023/v35i307459